HoV. Current concepts in the management of hepatopulmonary syndrome. Vasc Health Risk Manag. 2008;4:1035-1041.
2.
KleigmanRMStantonBFSt GemeJW3rdSchorNF, et al. Manifestations of liver disease. In: KliegmanRSt GemeJ, eds. Nelson Textbook of Pediatrics. 21st ed.Amsterdam, Netherlands: Elsevier; 2019:8316-8323.
3.
NoliKSolomonMGoldingFCharronMLingSC. Prevalence of hepatopulmonary syndrome in children. J Pediatr. 2008;121:e522-e527.
4.
CampAV. Hematologic toxicity from penicillamine in rheumatoid arthritis. J Rheumatol Suppl. 1981;7:164-165.
5.
Rodriguez-RoisinRKrowkaMJHervePHFallonMB; ERS Task Force Pulmonary-Hepatic Vascular Disorders (PHD) Scientific Committee. Pulmonary–hepatic vascular disorders (PHD). Eur Respir J. 2004;24:861-880.
6.
LeeWSWongSYIvyDDSokolRJ. Hepatopulmonary syndrome and portopulmonary hypertension in children: recent advances in diagnosis and management. J Pediatr. 2018;196:14-21.e1.
7.
Porres-AguilarMGallegos-OrozcoJFGarciaHAguirreJMacias-RodriguezRUTorre-DelgadilloA. Pulmonary vascular complications in portal hypertension and liver disease: a concise review. Revista de gastroenterologia de Mexico. 2013;78(1):35-44.
8.
SoulaidopoulosSCholongitasEGiannakoulasGVlachouMGoulisI. Review article: update on current and emergent data on hepatopulmonary syndrome. World J Gastroenterol. 2018;24:1285-1298.
